Y
Younger W.-Y. Yu
Publications - 64
Citations - 3338
Younger W.-Y. Yu is an academic researcher. The author has contributed to research in topics: Major depressive disorder & Fluoxetine. The author has an hindex of 33, co-authored 64 publications receiving 3160 citations.
Papers
More filters
Journal ArticleDOI
Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response.
TL;DR: A trend to improved 4‐week‐fluoxetine antidepressant response was demonstrated for heterozygous patients in comparison to homozygous analogs, suggesting the BDNF polymorphism investigated plays no major role in the pathogenesis of MDD.
Journal ArticleDOI
Association study of a Monoamine oxidase A gene promoter polymorphism with major depressive disorder and antidepressant response
TL;DR: The findings suggest that the MAOA-uVNTR may be involved in the pathogenesis of MDD and the antidepressant therapeutic mechanisms in Chinese population, and that there may be a gender effect in this association.
Journal ArticleDOI
Association study of the interleukin-1 beta (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response.
TL;DR: Patients with major depressive disorder who were homozygous for the -511T allele of the IL-1beta gene had a trend of less severity of depressive symptoms and more favorable fluoxetine therapeutic response than -511C carriers.
Journal ArticleDOI
Association study of a functional catechol-O-methyltransferase-gene polymorphism and cognitive function in healthy females.
Shih-Jen Tsai,Younger W.-Y. Yu,Tai Jui Chen,Jen Yeu Chen,Ying Jay Liou,Ming Chao Chen,Chen-Jee Hong +6 more
TL;DR: Although the COMT Val158Met genetic polymorphism may play a role in cognitive function, ethnicity and testing method may affect the association, the results demonstrate that subjects bearing the Met/Met homozygote have significantly lower mean P300 latencies than do analogs bearing the Val allele.
Journal ArticleDOI
An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients.
TL;DR: The finding suggests that this BDNF-gene Val66Met polymorphism may be related to schizophrenia pathogenesis in patients responsive to clozapine treatment and no significant difference in clozAPine therapeutic response was demonstrated comparing the three Val66 Met-genotype subgroups.